PDACMESOPANC-01NCT05895214
Mesopancreas Study in Pancreatic Cancer
An observational study of PDAC and Pancreatoduodenectomy, run by Heinrich-Heine University, Duesseldorf at 1 site in Germany.
Trial summary
After the Introduction of the pathological circumferential resection margin (CRM status by LEEPP Protocol), residual cancer (R1 resection) was most often found in the dorsal and medial resection margins. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- PDAC, Pancreatoduodenectomy, Margin, Resection
- What is being tested?
- oncological relevance of the mesopancreas
- Type of treatment
- Surgery or procedure
- How many people
- 500 participants
- Where
- 1 siteGermany
- Study dates
- 1 Jun 2023to 1 Jan 2027
- How long will I take part?
- 24 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Consecutive treated patients who are diagnosed with PDAC and received upfront surgical resection or neoadjuvant treatment prior to surgery
Who may be able to join
- All patients age ≥18 years who are admitted for primary surgery or patients who Received neoadjuvant therapy prior to surgery
- CRM analysis through Pathologic Institute in study centre already implemented (see LEEPP protocol Menon et al (2009) Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB 11(1):18-24)
- Preoperative computed-tomographic Imaging (biphasic) prior to surgery (if resected without neoadjuvant treatment)
- Pre-chemotherapeutic computed-tomographic and post-chemotherapeutic computed-tomographic if neoadjuvantly treated (biphasic).
- indepth information of surgical procedure (pancreatic tail preserved:yes/no, pylorus preserved resection: yes/no, venous resection: complete/partial/no, arterial resection: complete/partial/no)
Who cannot join
- Palliation
- Abort of operative procedure
- No preoperative computed-tomography for staging
- No pathological CRM Implementation according to the LEEPP
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Germany1 site
University Hospital Duesseldorf, Heinrich Heine University
Düsseldorf
About this study
Official title: MESOPANC-01 Study: The Mesopancreas and the Ductal Adenocarcinoma of the Pancreatic Head: From Preoperative Imaging to Histopathological and Surgical Outcome
After the Introduction of the pathological circumferential resection margin (CRM status by LEEPP Protocol), residual cancer (R1 resection) was most often found in the dorsal and medial resection margins. Yet only the medial resection margin is preoperatively evaluated during staging, while the dorsal resection margin which embeds the mesopancreatic fat and thus resembles the area of the mesopancreas, is not considered during preoperative assessment for resectability. Local recurrence is similarly prevalent as systemic relapse, and revised lower rates of R0CRM- resections through the LEEPP protocol explained the poor local tumor control. The aim of this study is to interdisciplinary approach the circumferential infiltration status of the PDAC concentrating foremost on the mesopancreas of the dorsal resection margin by including anatomic and embryologic derived perspectives.
Read the detailed description
For patients with a ductal adenocarcinoma of the pancreatic head (PDAC) pathological evaluation of the pancreatoduodenectomy specimen has endured a redefined process. After the Introduction of the pathological circumferential resection margin, residual cancer (R1 resection) was most often found in the dorsal and medial resection margins. Yet only the medial resection margin is preoperatively evaluated by staging and utilized during assessment of resectability. The dorsal resection margin which resides residual cancer (R1 resection) at a similar rate compared to the medial resection margin, is not considered during preoperative assessment for resectability. After the inclusion of the pathological LEEPP protocol true R0 resection rates have dropped to ~30%.
Next to the poor systemic tumor control and thus early detected relapse in PDAC patients, local recurrence is evenly at risk and remains an ungoing dilemma. Revised pathological outcome by the implemented LEEPP protocol explains the poor local tumor control.
The aim of this study is to interdisciplinary approach the circumferential infiltration status of the PDAC concentrating foremost on the dorsal resection margin by including anatomic and embryologic derived perspectives.
These perspectives have already been implemented by complete mesocolic and total mesorectal excision. The mesocolon of the ascending colon is embedded dorsally by fascia sheets, resulted by the embryologic fusion process, and the anatomic landmark of this fascia sheet has gained significant clinical relevance for radical surgical resection (Toldt fascia for total mesocolic excision). While surgical perspectives for the colorectal system have included the anatomic and embryologic nature of the colon and rectum, these landmarks and the idea of ''compartment anatomy'' are not implemented during pancreatoduodenectomy.
It seems rational to suggest that redefined surgical standards for colorectal cancer patients with implemented fascial sheets as anatomic landmarks could be translated to the pancreas as well. Similar to the ascending colon; the pancreas remains secondary retroperitoneal. The Treitz fascia is a cranio-medial extension of the toldts fascia, which again is an anatomic landmark for total mesocolic excision. The superior mesenteric artery serves as an anchor point for the embryologic rotation process of the pancreas until it remains secondary retroperitoneal. From an anatomic and embryologic point of view, there should not be any doubt for the existence of a mesopancreas.
The medial resection margin after pancreatoduodenectomy is resembled mostly by the portal confluens and does not embed any peripancreatic fat from the mesopancreas, underlining the different embryologic anlage between the pancreas and the portal venous system. The mesopancreas is located underneath the portal confluens, between the duodenum/pancreatic tissue and the inferior caval vein/abdominal aorta and continually encompasses the SMA. The dorsal resection margin during pancreatoduodenectomy resembles the mesopancreas and the aim of this multicentric prospective study is to study the oncological relevance of the mesopancreas.
Neoadjuvant therapy is a rising option for PDAC patients, and resectability criteria have been implemented to adequately stage these patients prior to therapy initiation. Current guidelines recommend to preoperatively investigate the medial vascular axis which represents the medial vascular groove. Patients are therefore sub-grouped into primary resectable, borderline resectable and non resectable mainly on the presumed infiltration status of the portomesenteric system.
In summary, the infiltration status of the PDAC is mainly being concentrated on the vascular groove. However, the dorsal resection margin, which is evenly at risk for incomplete resection (CRM assessment), is not considered during resectability stratification. Steps to secure or preoperatively assess this mesopancreatic area are not considered yet.
To stratify patients adequately for individualized therapy (neoadjuvant treatment vs surgery) a circumferential assessment, is crucial. Yet a circumferential assessment of the PDAC is provided only pathologically. In our opinion to realize a complete frame of tumor extensions a circumferential assessment should be implemented radiographically and surgically as well.
This observational study in patients with a ductal adenocarcinoma of the pancreatic head (PDAC) is of a prospective multicentric nature. In this study the mode of multimodal treatment, pre-operative computed tomographic staging, biological status (CA-19-9 values) are analyzed in a prospective consecutive treated patient cohort with respect to the infiltration status of the mesopancreas. The infiltration status of the mesopancreas is histopathologically analyzed while evaluating the dorsal resection margin for resection margin status (status positive/negative, depth of invasion in mm, depth of mesopancreas in mm, status of intact fascia sheet). No control group or placebo group exists.
The aim of this study is to analyze the oncological relevance of mesopancreatic fat infiltration both in upfront resected and neoadjuvant treated PDAC patients and to evaluate the feasibility of computed tomographic staging and preoperative serologic CA 19-9 values to predict the mesopancreatic infiltration status.
The histopathological analysis in each study center is an obligatory tool in order to postoperatively stage the PDAC. For this instance, the mesopancreatic fat infiltration status is analyzed in each respective study center. The radiographic analysis of the mesopancreas has yet not been standardized. For this mater, preoperative and peri-chemotherapeutic CT slides are centrally evaluated by the leading study initiators.
- Conditions
- PDAC, Pancreatoduodenectomy, Margin, Resection, Surgery, Local Recurrent Tumor
- Being tested
- oncological relevance of the mesopancreas
- Medical subject headings
- Margins of Excision
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
oncological relevance of the mesopancreasProcedure or surgery
Invasion status Invasion depth in mm Depth of mesopancreas in mm Treitz fascia intact (histopathological examination)
| Study group | Role | What they receive |
|---|---|---|
| patients who received primary surgery | preoperative CT scans available for assessing resectability criteria and presumed mesopancreatic infiltration status (CT scans are centrally evaluated) UICC 8th edition staging including CRM Tumor size in mm measured twice perpendicular Age Sex CA 19-9 values (preoperative) ECOG status BMI Type of PD (tail preserved vs total PD) simultaneous vessel resection (complete, partial; combined arterial and venous) Receives: Procedure: oncological relevance of the mesopancreas | |
| patients who received neoadjuvant treatment prior to surgery | Peri-therapeutic CT scans available for assessing resectability criteria and presumed mesopancreatic infiltration status (CT scans are centrally evaluated) UICC 8th edition staging including CRM Tumor size in mm measured twice perpendicular Age Sex CA 19-9 values (peri-therapeutic) ECOG status BMI Type of neoadjuvant Therapy Type of PD (tail preserved vs total PD), simultaneous vessel resection (complete, partial; combined arterial and venous) Tumor response according to CAP Receives: Procedure: oncological relevance of the mesopancreas |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of mesopancreatic infiltration in a multicentric setting.
Rate of mesopancreatic fat infiltration
Measured: through study completion, an average of 1 year
Statistical comparison of the mesopancreatic infiltration status with known oncologically relevant histopathological staging factors: is there a more aggressive tumor biology or an unfavorable tumor topography
Status of MP infiltration (pathologically analysed) vs. UICC and AJCC staging system (questionnaire from pathological staging reporting)
Measured: through study completion, an average of 1 year
Statistical comparison of mesopancreatic infiltration status with the CRM of the dorsal resection margin and with the entire CRM
Status of MP infiltration (pathologically analysed) vs. R-status (R0CRM- vs. R0CRM+/R1)(questionnaire from pathological staging reporting)
Measured: through study completion, an average of 1 year
Prediction value of density analyses in computed tomography (Hounsfield Unit) with mesopancreatic infiltration status in primary and neoadjuvantly patients
Density score of mesopancreas (HU) vs. Infiltration status of MP (Hounsfield Unit scale resembles the density assessment during computed tomography)(Hypothesis: higher HU measurements indicate higher risk for mesopancreatic fat infiltration) (minimum HU value: air -1000HU, maximum HU value: gold +30000 HU)
Measured: through study completion, an average of 1 year
Secondary outcomes (2)
Rate of mesopancreatic infiltration in primary and borderline resectable pancreatic head carcinomas (classification of resectability using the well-known ABC scheme)
Status of MP infiltration vs. resectability status
Measured: through study completion, an average of 1 year
Incidence rate of mesopancreatic infiltration between neoadjuvant treated and primary resected patients (matched-pairs analysis: both patient groups (neoadjuvant vs. primary resected) must have similar resectability criteria).
Status of MP infiltration vs. treatment protocol (matched pair analysis)
Measured: through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jun 2023
- Study start1 Jun 2023 (estimated)
- Primary completion1 Jan 2025 (estimated)
- Study completion1 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for PDACStudies of the same condition, open and under way.
- More trials run by Heinrich-Heine University, DuesseldorfThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
- Target duration
- 24 Months
Sponsor and investigators
- Lead sponsor
- Heinrich-Heine University, Duesseldorf
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Sami Alexander Safi, MD, Principal investigator, Department of Surgery (A), University Hospital of Duesseldorf of the Heinrich Heine University Duesseldorf, Germany
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05895214
- Sponsor's protocol ID
- DRKS000295
- Acronym
- MESOPANC-01
- Status last verified
- May 2023
- First submitted
- 25 Apr 2023
- Last updated
- 8 Jun 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Study Protocol Agreement between Sponsor and research sight
Publications
Safi SA, Haeberle L, Fluegen G, Lehwald-Tywuschik N, Krieg A, Keitel V, Luedde T, Esposito I, Rehders A, Knoefel WT. Mesopancreatic excision for pancreatic ductal adenocarcinoma improves local disease control and survival. Pancreatology. 2021 Jun;21(4):787-795. doi: 10.1016/j.pan.2021.02.024. Epub 2021 Mar 17.
PubMed 33775563Safi SA, Haeberle L, Heuveldop S, Kroepil P, Fung S, Rehders A, Keitel V, Luedde T, Fuerst G, Esposito I, Ziayee F, Antoch G, Knoefel WT, Fluegen G. Pre-Operative MDCT Staging Predicts Mesopancreatic Fat Infiltration-A Novel Marker for Neoadjuvant Treatment? Cancers (Basel). 2021 Aug 28;13(17):4361. doi: 10.3390/cancers13174361.
PubMed 34503170Safi SA, Haeberle L, Rehders A, Fung S, Vaghiri S, Roderburg C, Luedde T, Ziayee F, Esposito I, Fluegen G, Knoefel WT. Neoadjuvant Treatment Lowers the Risk of Mesopancreatic Fat Infiltration and Local Recurrence in Patients with Pancreatic Cancer. Cancers (Basel). 2021 Dec 23;14(1):68. doi: 10.3390/cancers14010068.
PubMed 35008232Esposito I, Kleeff J, Bergmann F, Reiser C, Herpel E, Friess H, Schirmacher P, Buchler MW. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008 Jun;15(6):1651-60. doi: 10.1245/s10434-008-9839-8. Epub 2008 Mar 20.
PubMed 18351300Menon KV, Gomez D, Smith AM, Anthoney A, Verbeke CS. Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford). 2009 Feb;11(1):18-24. doi: 10.1111/j.1477-2574.2008.00013.x.
PubMed 19590619
Study at a glance
From the registry record, last updated by the sponsor on 8 Jun 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- MESOPANC-01 Study: The Mesopancreas and the Ductal Adenocarcinoma of the Pancreatic Head: From Preoperative Imaging to Histopathological and Surgical Outcome
- ClinicalTrials.gov ID
- NCT05895214
- Acronym / sponsor ID
- MESOPANC-01 / DRKS000295
- Conditions
- PDAC, Pancreatoduodenectomy, Margin, Resection, Surgery, Local Recurrent Tumor
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Heinrich-Heine University, DuesseldorfUniversity, hospital or other
- Study start
- 1 Jun 2023 (estimated)
- Primary completion
- 1 Jan 2025 (estimated)
- Study completion
- 1 Jan 2027 (estimated)
- First posted
- 8 Jun 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
After the Introduction of the pathological circumferential resection margin (CRM status by LEEPP Protocol), residual cancer (R1 resection) was most often found in the dorsal and medial resection margins. Yet only the medial resection margin is preoperatively evaluated during staging, while the dorsal resection margin which embeds the mesopancreatic fat and thus resembles the area of the mesopancreas, is not considered during preoperative assessment for resectability. Local recurrence is similarly prevalent as systemic relapse, and revised lower rates of R0CRM- resections through the LEEPP protocol explained the poor local tumor control. The aim of this study is to interdisciplinary approach the circumferential infiltration status of the PDAC concentrating foremost on the mesopancreas of the dorsal resection margin by including anatomic and embryologic derived perspectives.
Detailed description
For patients with a ductal adenocarcinoma of the pancreatic head (PDAC) pathological evaluation of the pancreatoduodenectomy specimen has endured a redefined process. After the Introduction of the pathological circumferential resection margin, residual cancer (R1 resection) was most often found in the dorsal and medial resection margins. Yet only the medial resection margin is preoperatively evaluated by staging and utilized during assessment of resectability. The dorsal resection margin which resides residual cancer (R1 resection) at a similar rate compared to the medial resection margin, is not considered during preoperative assessment for resectability. After the inclusion of the pathological LEEPP protocol true R0 resection rates have dropped to ~30%.
Next to the poor systemic tumor control and thus early detected relapse in PDAC patients, local recurrence is evenly at risk and remains an ungoing dilemma. Revised pathological outcome by the implemented LEEPP protocol explains the poor local tumor control.
The aim of this study is to interdisciplinary approach the circumferential infiltration status of the PDAC concentrating foremost on the dorsal resection margin by including anatomic and embryologic derived perspectives.
These perspectives have already been implemented by complete mesocolic and total mesorectal excision. The mesocolon of the ascending colon is embedded dorsally by fascia sheets, resulted by the embryologic fusion process, and the anatomic landmark of this fascia sheet has gained significant clinical relevance for radical surgical resection (Toldt fascia for total mesocolic excision). While surgical perspectives for the colorectal system have included the anatomic and embryologic nature of the colon and rectum, these landmarks and the idea of ''compartment anatomy'' are not implemented during pancreatoduodenectomy.
It seems rational to suggest that redefined surgical standards for colorectal cancer patients with implemented fascial sheets as anatomic landmarks could be translated to the pancreas as well. Similar to the ascending colon; the pancreas remains secondary retroperitoneal. The Treitz fascia is a cranio-medial extension of the toldts fascia, which again is an anatomic landmark for total mesocolic excision. The superior mesenteric artery serves as an anchor point for the embryologic rotation process of the pancreas until it remains secondary retroperitoneal. From an anatomic and embryologic point of view, there should not be any doubt for the existence of a mesopancreas.
The medial resection margin after pancreatoduodenectomy is resembled mostly by the portal confluens and does not embed any peripancreatic fat from the mesopancreas, underlining the different embryologic anlage between the pancreas and the portal venous system. The mesopancreas is located underneath the portal confluens, between the duodenum/pancreatic tissue and the inferior caval vein/abdominal aorta and continually encompasses the SMA. The dorsal resection margin during pancreatoduodenectomy resembles the mesopancreas and the aim of this multicentric prospective study is to study the oncological relevance of the mesopancreas.
Neoadjuvant therapy is a rising option for PDAC patients, and resectability criteria have been implemented to adequately stage these patients prior to therapy initiation. Current guidelines recommend to preoperatively investigate the medial vascular axis which represents the medial vascular groove. Patients are therefore sub-grouped into primary resectable, borderline resectable and non resectable mainly on the presumed infiltration status of the portomesenteric system.
In summary, the infiltration status of the PDAC is mainly being concentrated on the vascular groove. However, the dorsal resection margin, which is evenly at risk for incomplete resection (CRM assessment), is not considered during resectability stratification. Steps to secure or preoperatively assess this mesopancreatic area are not considered yet.
To stratify patients adequately for individualized therapy (neoadjuvant treatment vs surgery) a circumferential assessment, is crucial. Yet a circumferential assessment of the PDAC is provided only pathologically. In our opinion to realize a complete frame of tumor extensions a circumferential assessment should be implemented radiographically and surgically as well.
This observational study in patients with a ductal adenocarcinoma of the pancreatic head (PDAC) is of a prospective multicentric nature. In this study the mode of multimodal treatment, pre-operative computed tomographic staging, biological status (CA-19-9 values) are analyzed in a prospective consecutive treated patient cohort with respect to the infiltration status of the mesopancreas. The infiltration status of the mesopancreas is histopathologically analyzed while evaluating the dorsal resection margin for resection margin status (status positive/negative, depth of invasion in mm, depth of mesopancreas in mm, status of intact fascia sheet). No control group or placebo group exists.
The aim of this study is to analyze the oncological relevance of mesopancreatic fat infiltration both in upfront resected and neoadjuvant treated PDAC patients and to evaluate the feasibility of computed tomographic staging and preoperative serologic CA 19-9 values to predict the mesopancreatic infiltration status.
The histopathological analysis in each study center is an obligatory tool in order to postoperatively stage the PDAC. For this instance, the mesopancreatic fat infiltration status is analyzed in each respective study center. The radiographic analysis of the mesopancreas has yet not been standardized. For this mater, preoperative and peri-chemotherapeutic CT slides are centrally evaluated by the leading study initiators.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 24 Months
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| patients who received primary surgery | – | Procedure: oncological relevance of the mesopancreaspreoperative CT scans available for assessing resectability criteria and presumed mesopancreatic infiltration status (CT scans are centrally evaluated) UICC 8th edition staging including CRM Tumor size in mm measured twice perpendicular Age Sex CA 19-9 values (preoperative) ECOG status BMI Type of PD (tail preserved vs total PD) simultaneous vessel resection (complete, partial; combined arterial and venous) |
| patients who received neoadjuvant treatment prior to surgery | – | Procedure: oncological relevance of the mesopancreasPeri-therapeutic CT scans available for assessing resectability criteria and presumed mesopancreatic infiltration status (CT scans are centrally evaluated) UICC 8th edition staging including CRM Tumor size in mm measured twice perpendicular Age Sex CA 19-9 values (peri-therapeutic) ECOG status BMI Type of neoadjuvant Therapy Type of PD (tail preserved vs total PD), simultaneous vessel resection (complete, partial; combined arterial and venous) Tumor response according to CAP |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Consecutive treated patients who are diagnosed with PDAC and received upfront surgical resection or neoadjuvant treatment prior to surgery
Key inclusion criteria (5 listed)
- All patients age ≥18 years who are admitted for primary surgery or patients who Received neoadjuvant therapy prior to surgery
- CRM analysis through Pathologic Institute in study centre already implemented (see LEEPP protocol Menon et al (2009) Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB 11(1):18-24)
- Preoperative computed-tomographic Imaging (biphasic) prior to surgery (if resected without neoadjuvant treatment)
- Pre-chemotherapeutic computed-tomographic and post-chemotherapeutic computed-tomographic if neoadjuvantly treated (biphasic).
- indepth information of surgical procedure (pancreatic tail preserved:yes/no, pylorus preserved resection: yes/no, venous resection: complete/partial/no, arterial resection: complete/partial/no)
Key exclusion criteria (4 listed)
- Palliation
- Abort of operative procedure
- No preoperative computed-tomography for staging
- No pathological CRM Implementation according to the LEEPP
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| oncological relevance of the mesopancreasInvasion status Invasion depth in mm Depth of mesopancreas in mm Treitz fascia intact (histopathological examination) | Procedure or surgery | patients who received neoadjuvant treatment prior to surgery, patients who received primary surgery |
Primary outcome
Rate of mesopancreatic infiltration in a multicentric setting.
Time frame: through study completion, an average of 1 year
Rate of mesopancreatic fat infiltration
Statistical comparison of the mesopancreatic infiltration status with known oncologically relevant histopathological staging factors: is there a more aggressive tumor biology or an unfavorable tumor topography
Time frame: through study completion, an average of 1 year
Status of MP infiltration (pathologically analysed) vs. UICC and AJCC staging system (questionnaire from pathological staging reporting)
Statistical comparison of mesopancreatic infiltration status with the CRM of the dorsal resection margin and with the entire CRM
Time frame: through study completion, an average of 1 year
Status of MP infiltration (pathologically analysed) vs. R-status (R0CRM- vs. R0CRM+/R1)(questionnaire from pathological staging reporting)
Prediction value of density analyses in computed tomography (Hounsfield Unit) with mesopancreatic infiltration status in primary and neoadjuvantly patients
Time frame: through study completion, an average of 1 year
Density score of mesopancreas (HU) vs. Infiltration status of MP (Hounsfield Unit scale resembles the density assessment during computed tomography)(Hypothesis: higher HU measurements indicate higher risk for mesopancreatic fat infiltration) (minimum HU value: air -1000HU, maximum HU value: gold +30000 HU)
2 secondary outcomes
Rate of mesopancreatic infiltration in primary and borderline resectable pancreatic head carcinomas (classification of resectability using the well-known ABC scheme)
Time frame: through study completion, an average of 1 year
Incidence rate of mesopancreatic infiltration between neoadjuvant treated and primary resected patients (matched-pairs analysis: both patient groups (neoadjuvant vs. primary resected) must have similar resectability criteria).
Time frame: through study completion, an average of 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jun 2023.
- Background: PubMed 33775563Safi SA, Haeberle L, Fluegen G, Lehwald-Tywuschik N, Krieg A, Keitel V, Luedde T, Esposito I, Rehders A, Knoefel WT. Mesopancreatic excision for pancreatic ductal adenocarcinoma improves local disease control and survival. Pancreatology. 2021 Jun;21(4):787-795. doi: 10.1016/j.pan.2021.02.024. Epub 2021 Mar 17.
- Background: PubMed 34503170Safi SA, Haeberle L, Heuveldop S, Kroepil P, Fung S, Rehders A, Keitel V, Luedde T, Fuerst G, Esposito I, Ziayee F, Antoch G, Knoefel WT, Fluegen G. Pre-Operative MDCT Staging Predicts Mesopancreatic Fat Infiltration-A Novel Marker for Neoadjuvant Treatment? Cancers (Basel). 2021 Aug 28;13(17):4361. doi: 10.3390/cancers13174361.
- Background: PubMed 35008232Safi SA, Haeberle L, Rehders A, Fung S, Vaghiri S, Roderburg C, Luedde T, Ziayee F, Esposito I, Fluegen G, Knoefel WT. Neoadjuvant Treatment Lowers the Risk of Mesopancreatic Fat Infiltration and Local Recurrence in Patients with Pancreatic Cancer. Cancers (Basel). 2021 Dec 23;14(1):68. doi: 10.3390/cancers14010068.
- Background: PubMed 18351300Esposito I, Kleeff J, Bergmann F, Reiser C, Herpel E, Friess H, Schirmacher P, Buchler MW. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008 Jun;15(6):1651-60. doi: 10.1245/s10434-008-9839-8. Epub 2008 Mar 20.
- Background: PubMed 19590619Menon KV, Gomez D, Smith AM, Anthoney A, Verbeke CS. Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford). 2009 Feb;11(1):18-24. doi: 10.1111/j.1477-2574.2008.00013.x.
- Individual participant dataSharing planned: Undecided. Study Protocol Agreement between Sponsor and research sight
Related trials for PDAC
RecruitingPhase 1
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 3
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 2
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
RecruitingPhase 3
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Sami Alexander Safi, MD principal investigator
Department of Surgery (A), University Hospital of Duesseldorf of the Heinrich Heine University Duesseldorf, Germany
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of PDAC and Pancreatoduodenectomy, run by Heinrich-Heine University, Duesseldorf at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 8 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sami Alexander Safi, MD (+4916097937947, safi@hhu.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of mesopancreatic infiltration in a multicentric setting. (time frame: through study completion, an average of 1 year). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05895214, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jun 2023.